Company / Net Income
NEKTAR THERAPEUTICS Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$164.1M
FY2025
5-year range
-$523.8M / -$164.1M
FY2021-FY2025
Trend
+40.6%
vs FY2024
Sector context
#140 of 216
Health Care
What the data says
At -$164M, NEKTAR THERAPEUTICS's net income ranks #140 of 216 in the Health Care sector. Net Income has fluctuated over the past 10 years, ranging from -$524M in FY2023 to $681M in FY2020.
Based on SEC 10-K filings.
-$164M in FY2025.
Improved from -$524M to -$164M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#140 of 216 in Health CareTop 65% of 216This company -$164.1M Sector average $454.1M
▼
-136.1% below sector average
Key checks
Key Insights
- In FY2025, net income increased 40.6% year-over-year.
- Ranks #140 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$164.1M | +40.6% |
| FY2024 | -$276.1M | +47.3% |
| FY2023 | -$523.8M | -42.3% |
| FY2022 | -$368.2M | +29.7% |
| FY2021 | -$523.8M | -176.9% |
| FY2020 | $681.3M | +804.6% |
| FY2019 | -$96.7M | +37.0% |
| FY2018 | -$153.5M | -58.8% |
| FY2017 | -$96.7M | -79.3% |
| FY2016 | -$53.9M | +33.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026